GlassScriptPhysician profile
Farrah Timmol
NPI 1184458689
$1,618.54
in general payments reported to CMS, 2019-2025
20 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $176 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.80 |
| Education | $162.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $209.64 | 2025 | Veozah |
| Novo Nordisk INC | $198.01 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $196.76 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $193.98 | 2025 | Zepbound, Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $125.24 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $109.84 | 2025 | Trelegy Ellipta |
| Pfizer INC. | $87.02 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $87.02 | 2025 | Rexulti |
| Abbvie INC. | $66.00 | 2025 | |
| Axsome Therapeutics, INC. | $60.30 | 2024-2025 | Auvelity, Sunosi |
| Exact Sciences Corporation | $51.83 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $42.31 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Takeda Pharmaceuticals U.S.A., INC. | $34.49 | 2025 | Eohilia |
| Amgen INC. | $30.14 | 2025 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $30.12 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.33 | 2025 | Gardasil 9, Capvaxive |
| Medtronic, INC. | $23.22 | 2025 | Inpen Smart Insulin Delivery System |
| Actelion Pharmaceuticals US, INC. | $15.82 | 2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $15.56 | 2024 | |
| Paratek Pharmaceuticals, INC. | $13.91 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrah Timmol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.